AFFILIATIONS
1 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
2 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
3 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
4 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
5 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
6 Peking University First Hospital, Beijing, China
7 Peking University Third Hospital, Beijing, China
8 Chinese PLA General Hospital, Beijing, China
9 Beijing Hospital, Beijing, China
10 The Sixth Medical Center of PLA General Hospital, Beijing, China
11 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
12 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
13 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
14 Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Collaborative Innovation Center of Hematology, Beijing, China, National Clinical Research Center for Hematologic Disease, Beijing, China, Peking University People's Hospital, Beijing, China
ABSTRACT
Background
Managing patients with primary immune thrombocytopenia (ITP) who have failed multiple lines of therapy remains a major challenge. The mechanisms underlying refractory disease are poorly understood. Our previous work revealed a“dual-axis injury” pattern of sympathetic nerve in refractory ITP, affecting perivascular niches in the bone marrow and sympathetic innervation in the spleen. This dual-axis injury impairs bone marrow megakaryopoiesis (Blood Adv, 2019) and disrupts splenic T-cell homeostasis while skewing macrophage polarization (J Thromb Haemost, 2023). Terbutaline, a selective β2-adrenergic receptor (β2-AR) agonist, directly activates sympathetic β2-AR signaling to restore immune balance in vitro and in vivo (ASH oral presentation, 2024), making it a promising treatment option. We therefore conducted a multicenter randomized trial to assess the efficacy and safety of terbutaline in corticosteroid-resistant or relapsed ITP.
Methods
This randomized, controlled, open-label, multicenter trial enrolled adult patients with corticosteroid-resistant or relapsed ITP from 6 tertiary centers in China. Eligible patients with a platelet count <30×10?/L or clinically significant bleeding at enrollment were randomized 1:1 to receive oral terbutaline 2.5 mg three times daily plus danazol 200 mg twice daily, or danazol monotherapy for 16 weeks. The primary endpoint was initial overall response (OR), defined as platelet count ≥30×10?/L with at least a doubling of baseline without bleeding. The secondary endpoint was 6-month sustained response (SR), defined as platelet count ≥50×10?/L at ≥4 of 6 scheduled visits between weeks 16 and 26, or platelet count between 30×10?/L and 50×10?/L with at least a doubling of baseline. This trial was registered with (NCT05494307).
Results
Between September 1, 2022, and December 31, 2024, 276 patients were screened for eligibility; 60 were excluded, and 216 were randomly assigned. All 216 patients were included in the intention-to-treat analysis: 108 in the terbutaline plus danazol group and 108 in the danazol monotherapy group. The median age was 46 years (range 18–76). All patients had failed corticosteroids; 128 (59.3%) had received three or more prior therapies, with a median of 3 prior lines (range 1–9). Baseline platelet count was 15×10?/L (range 2–29). The two groups were well balanced for all baseline characteristics.
The OR rate was significantly higher with terbutaline plus danazol than with danazol alone: 50.9% (55/108) vs 25.9% (28/108) (difference 25.0 percentage points; 95% CI, 12.6–37.4; P<0.001). Among responders, median time to response was 42 days (IQR 28–56) in the combination group vs 56 days (IQR 42–70) in the monotherapy group. SR at 26 weeks was achieved by 40.7% (44/108) of patients in the combination group vs 14.8% (16/108) in the monotherapy group (difference 25.9 percentage points; 95% CI, 14.5–37.3; P<0.001). Median duration of response among responders was 34 weeks (IQR 24–41) vs 18 weeks (IQR 12–26) (P=0.006).
Clinically significant bleeding (WHO grade ≥2) was present in 32.4% (35/108) of patients in the terbutaline plus danazol group and 33.3% (36/108) in the danazol monotherapy group at baseline, which decreased to 9.3% (10/108) and 18.5% (20/108) at week 16, respectively (between-group difference: -9.3 percentage points; 95% CI -18.2 to -0.4; P=0.045). A significantly lower proportion of patients in the terbutaline plus danazol group had clinically significant bleeding at week 26 compared with the danazol monotherapy group (OR 0.41, 95% CI 0.18–0.94; P=0.035).
Adverse events (AEs) were reported in 63.0% (68/108) of patients receiving terbutaline plus danazol, mostly grade 1–2. The most common AEs in the combination group were tremor (27.8%, 30/108), headache or dizziness (19.4%, 21/108), palpitations (15.7%, 17/108), and hypertension (9.3%, 10/108). One patient (0.9%) in the combination group discontinued treatment due to grade 3 tremor. No grade ≥4 AEs or treatment-related deaths occurred.
Conclusions
To our knowledge, this is the first study evaluating terbutaline in ITP, building on our mechanistic findings that β2-AR agonist restores immune balance. Our results show that terbutaline plus danazol significantly improves response rates and reduces bleeding, with a manageable safety profile, offering a promising oral option for patients with limited alternatives after multiple treatment failures.